Weight loss injections, particularly glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Wegovy, Ozempic) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Zepbound, Mounjaro), have transformed obesity management in recent years
Leiter LA, Bain SC, Hramiak I, Jdar E, Madsbad S, Gondolf T, Hansen T, Holst I, Lingvay I
The companys GLP-1 agonists for diabetes grew strongly, thanks to its once-weekly injectable Ozempic (semaglutide) which grew 119% to DKK 15 billion ($2.35 billion), overtaking Novo Nordisks older Victoza (liraglutide) product which requires dosing by injection every day
Is the dosing schedule the same for diabetes and weight management
Or considering a non-oral contraceptive such as the implant, IUD, patch etc